Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

Mehmet Sah İpek; Mehmet Emin Gunel; Erdal Ozbek

doi:10.1055/s-0038-1675582

Journal of Pediatric Infectious Diseases, Table of Contents

J Pediatr Infect Dis 2019; 14(03): 103-107
DOI: 10.1055/s-0038-1675582

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

Mehmet Sah İpek

¹Division of Neonatology, Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey

,

Mehmet Emin Gunel

²Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey

,

Erdal Ozbek

³Department of Microbiology, Diyarbakir Maternity and Children Hospital, Diyarbakir, Turkey

› Author Affiliations

Abstract

The off-label use of tigecycline to treat serious infections has been reported in pediatric patients. We report four newborn infants diagnosed with sepsis caused by extensively drug-resistant Klebsiella pneumoniae and successfully treated with tigecycline. If no alternative drugs are available, tigecycline may be considered as an option for nosocomial infections even in newborn infants. However, further reports are needed to establish its efficacy and safety.

Keywords

tigecycline - neonate - infection - thrombocytopenia

Full Text

References

References
1 Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther 2017; 15 (06) 605-612
2 Tygacil: FDA full prescribing information. June 1, 2016. Available at: http://www.fda.gov . Accessed December 15, 2017
3 Iosifidis E, Violaki A, Michalopoulou E. , et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc 2017; 6 (02) 123-128
4 Hurtado IC, Trujillo M, Restrepo A, Garcés C, Tamayo C, Mesa JG. Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae [Article in Spanish]. Rev Chilena Infectol 2012; 29 (03) 317-321
5 Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr 2016; 105 (10) e480-e484
6 Prot-Labarthe S, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J 2010; 29 (09) 890-891
7 Emiroglu M, Alkan G, Turk Dagi H. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics 2017; 139 (01) 139
8 Purdy J, Jouve S, Yan JL. , et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34 (02) 496-507.e1
9 Magiorakos AP, Srinivasan A, Carey RB. , et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18 (03) 268-281
10 Zeng J, Zhang L, Gao M. , et al. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia. Int J Infect Dis 2017; 61: 23-26
11 Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57 (04) 1756-1762
12 Ni W, Han Y, Liu J. , et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (11) e3126
13 Daikos GL, Tsaousi S, Tzouvelekis LS. , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (04) 2322-2328
14 Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F. , et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015; 70 (03) 905-913
15 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial. Pediatr Infect Dis J 2017; 36 (04) 358-363
16 Eckmann C, Heizmann W, Bodmann KF, von Eiff C, Petrik C, Loeschmann PA. Tigecycline in the treatment of patients with necrotizing skin and soft tissue infections due to multiresistant bacteria. Surg Infect (Larchmt) 2015; 16 (05) 618-625
17 Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133 (02) 309-314
18 İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: a case-control study. Pediatr Neonatol 2017; 58 (06) 490-496